RxDoctor Payments Data

Robert Izor, MD

Neurology · Austin, TXNPI 1164409108

Payments from drug & device makers

$36,317in general payments, 2019–2025

Across 807 payments — averaging $45.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$14K
  • Abbott$12K
  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • MDD US Operations, LLC$662
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$9,65027%
  • Speaking & faculty fees$10,02428%
  • Travel & lodging$7482%
  • Food & beverage$15,88644%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,317 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$625,363
Medicare patients
304
Services billed
14,532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl49$166,189
RytaryCarbidopa/Levodopa59$57,176
XadagoSafinamide Mesylate19$28,853
OngentysOpicapone13$17,802
NeuproRotigotine12$16,838
Carbidopa-Levodopa ErCarbidopa/Levodopa178$9,609
Selegiline Hcl51$9,077
Rasagiline Mesylate49$8,562
Entacapone26$5,117
AmantadineAmantadine Hcl84$4,987
Pramipexole ErPramipexole Di-Hcl13$3,379
Rivastigmine21$3,073
Carbidopa-LevodopaCarbidopa/Levodopa140$3,049
Primidone80$2,578
Pramipexole DihydrochloridePramipexole Di-Hcl38$1,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$662$166,18949 claims
Amneal Pharmaceuticals LLCRytary$397$57,17659 claims
Neurocrine Biosciences, Inc.Ongentys$579$17,80213 claims
UCB, Inc.Neupro$193$16,83812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →